Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946476 | 0.95 | S1PR1 (0.50) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL947190 | 0.95 | GAA (0.50) | GAAKCNH2TAAR1CYP2D6LTA4H | |
| SCHEMBL947963 | 0.94 | DRD2 (0.52) | GAAKCNH2FFAR1LTA4HMEN1 | |
| SCHEMBL950934 | 0.94 | S1PR1 (0.51) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL947834 | 0.93 | FFAR1 (0.56) | GAAFFAR1TAAR1CYP2D6LTA4H | |
| SCHEMBL949057 | 0.93 | S1PR1 (0.52) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL950419 | 0.93 | S1PR1 (0.52) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL948652 | 0.93 | S1PR1 (0.52) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL951103 | 0.93 | S1PR1 (0.52) | GAAKCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL947941 | 0.93 | S1PR1 (0.52) | GAAKCNH2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2883865-A1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8791159-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR2, S1PR3 | GAA 4659/4885KCNH2 1238/4885FFAR1 28/4885 |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR3, S1PR2 | GAA 4138/4885KCNH2 1903/4885FFAR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.